NGNE News & Events

Neurogene announced the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offering price per share of $30.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 666,666 shares of its common stock at a public offering price of $29.999999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.000001 per share and are exercisable immediately. The aggregate gross proceeds to Neurogene from the offering are expected to be approximately $125M before deducting underwriting discounts and commissions and other offering expenses payable by Neurogene, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on July 2, subject to the satisfaction of customary closing conditions. In addition, Neurogene has granted the underwriters an option for a period of 30 days to purchase up to an additional 624,999 shares at the public offering price, less underwriting discounts and commissions. Leerink Partners, Stifel, Guggenheim Securities, LifeSci Capital and William Blair are acting as joint bookrunning managers for the offering.

Leerink, Stifel, Guggenheim, LifeSci Capital and William Blair are acting as joint book running managers for the offering.

Neurogene announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. Neurogene intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the ongoing clinical development of NGN-401, pre-commercial activities for NGN-401 and for working capital and other general corporate purposes. Leerink Partners, Stifel, Guggenheim Securities, LifeSci Capital and William Blair are acting as joint bookrunning managers for the proposed offering.

Neurogene announced updated, positive data from its Phase 1/2 clinical trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. Across 10 participants, 47 total developmental milestones were gained, with both pediatric and adolescent/adult participants demonstrating clinical response and continued, progressive improvements through 30 months of follow-up, with no plateau or loss of milestones observed. Key highlights: 100% of participants improved in CGI-I score and gained greater than or equal to1 developmental milestone, with an average of 4.7 milestones per participant, and all gaining greater than or equal to1 developmental milestone in the past 12 months; Developmental milestones were gained in a progressive, stepwise sequence, suggesting a restart of development post-treatment; NGN-401 at the 1E15 vg dose remains generally well-tolerated as of data cutoff date of June 16, 2026; Dosing complete in the EmboldenTM registrational trial with no treatment-related SAEs or DLTs as of data cutoff date of June 16, 2026, with topline data anticipated in 2H 2027